Using pluripotent stem cell-derived NK cells, the team engineered CD276-targeted CAR-expressing NK cells and assessed their cytotoxicity against ESCC via a patient-specific organoid (PSO) model. The gene discussed is CD276; the disease is esophageal squamous cell carcinoma.